{"id":"ang-3777","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4650326","moleculeType":"Small molecule","molecularWeight":"176.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ANG-3777 is designed to mimic the biological activity of hepatocyte growth factor by binding to and activating the MET receptor tyrosine kinase. This activation promotes angiogenesis, tissue repair, and regeneration, particularly in ischemic tissues. The drug is being developed to treat conditions characterized by tissue damage and impaired vascular function.","oneSentence":"ANG-3777 is a hepatocyte growth factor (HGF) mimetic that activates the MET receptor to promote tissue repair and regeneration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:38.467Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic kidney disease"},{"name":"Peripheral artery disease"}]},"trialDetails":[{"nctId":"NCT02771509","phase":"PHASE2","title":"Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2017-02-24","conditions":"Acute Kidney Injury","enrollment":275},{"nctId":"NCT04958187","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2021-07","conditions":"Hemodialysis","enrollment":16},{"nctId":"NCT04931524","phase":"PHASE1","title":"A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2021-05-21","conditions":"Healthy","enrollment":6},{"nctId":"NCT02474667","phase":"PHASE3","title":"Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2016-03","conditions":"Delayed Graft Function","enrollment":253},{"nctId":"NCT04898907","phase":"PHASE1","title":"Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2021-06","conditions":"Healthy Volunteer","enrollment":48},{"nctId":"NCT04459676","phase":"PHASE2","title":"Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2020-07-31","conditions":"COVID-19, Pneumonia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hepatocyte growth factor mimetic","BB3"],"phase":"phase_3","status":"active","brandName":"ANG-3777","genericName":"ANG-3777","companyName":"Angion Biomedica Corp","companyId":"angion-biomedica-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ANG-3777 is a small molecule that acts as a hepatocyte growth factor receptor agonist. It is being studied in clinical trials for various conditions, including COVID-19 pneumonia, acute kidney injury, and hemodialysis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}